Diagnosing Crohn’s disease and ulcerative colitis requires a combination of blood tests, stool samples, imaging, and endoscopy. No single test confirms either condition. Instead, doctors piece together results from several tools to determine whether you have inflammatory bowel disease (IBD), and if so, which type. The process can take time: surveys show that 70% of people with Crohn’s disease and 48% of those with ulcerative colitis experience delays of more than a year between their first symptoms and a definitive diagnosis.
Blood and Stool Tests Come First
The diagnostic workup typically starts with blood and stool tests. These can’t confirm Crohn’s or ulcerative colitis on their own, but they help your doctor decide whether inflammation is present and whether more invasive testing is warranted.
Two common blood markers, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), measure general inflammation in your body. Elevated levels suggest something inflammatory is happening, but they don’t pinpoint where or why. Blood tests also check for anemia, which is common in IBD because chronic intestinal bleeding and poor nutrient absorption can deplete your iron and red blood cell counts.
The most useful screening tool before endoscopy is a stool test called fecal calprotectin. Calprotectin is a protein released by white blood cells when they flood into inflamed intestinal tissue. A result below 50 micrograms per gram makes IBD unlikely and can spare you an unnecessary colonoscopy. The 2025 American College of Gastroenterology guidelines use a cutoff of 50 to 100 micrograms per gram to distinguish inflammatory bowel conditions from non-inflammatory ones like irritable bowel syndrome. In children, raising the threshold to above 250 micrograms per gram (combined with elevated CRP and low hemoglobin) increases diagnostic accuracy to 97% specificity while still catching every true case.
Colonoscopy Is the Central Diagnostic Step
A colonoscopy is the most important test for diagnosing both conditions. A gastroenterologist threads a flexible camera through your colon, looking at the lining in real time and taking small tissue samples (biopsies) along the way. What the doctor sees during this exam, combined with what the biopsies show under a microscope, often determines your diagnosis.
The visual patterns differ between the two diseases. Ulcerative colitis typically starts in the rectum and extends upward in a continuous line with no gaps. Every stretch of affected tissue is inflamed. Crohn’s disease, by contrast, often skips areas, leaving patches of healthy tissue between inflamed spots. Crohn’s can also produce a cobblestone-like texture on the intestinal wall and deep, narrow ulcers that burrow into the tissue.
These visual clues are helpful, but not always definitive. About 10% to 15% of IBD cases initially can’t be classified as one or the other, a situation doctors call “indeterminate colitis.” Biopsy results and additional testing usually clarify things over time.
What Biopsies Reveal Under the Microscope
The tissue samples taken during colonoscopy go to a pathologist, who examines them for four main features: the architecture of the intestinal glands (called crypts), the types of immune cells present, whether certain white blood cells have invaded the crypt lining, and any damage to the surface cells.
In ulcerative colitis, the crypt architecture is usually more disrupted. Crypts become irregular, branched, and shortened. Collections of white blood cells can fill the crypt openings, forming what pathologists call crypt abscesses. These abscesses occur in both diseases but are more common in ulcerative colitis.
The hallmark microscopic finding in Crohn’s disease is something called a granuloma: a tiny cluster of activated immune cells that forms when the body walls off something it can’t eliminate. These granulomas are non-caseating, meaning they don’t have the dead-tissue center you’d see in tuberculosis. Finding one strongly favors a Crohn’s diagnosis, but granulomas only show up in a portion of Crohn’s biopsies. Their absence doesn’t rule it out.
Imaging for the Small Bowel
Colonoscopy can only reach the colon and the very end of the small intestine. Since Crohn’s disease can affect any part of the digestive tract, including deep sections of the small bowel that a scope can’t reach, imaging is often essential.
MR enterography (MRE) has become the preferred imaging method for evaluating Crohn’s disease. It uses magnetic resonance to produce detailed images without radiation, which matters because many IBD patients are young and will need repeated scans over their lifetime. MRE can detect bowel wall thickening, narrowing of the intestinal passage, fistulas (abnormal tunnels between loops of bowel or between the bowel and other organs), abscesses, and inflammation in the surrounding fat tissue. The 2025 ACG guidelines formally endorse it as a core part of Crohn’s staging.
CT enterography serves a similar purpose but involves radiation exposure. It’s generally reserved for emergencies, such as when a doctor suspects a perforation, obstruction, or abscess that needs rapid identification. CT is faster and more widely available, making it the go-to in acute situations.
Intestinal ultrasound is gaining recognition as a radiation-free, noninvasive option. It can assess bowel wall thickness and surrounding tissue changes at the bedside or in a clinic, and the latest guidelines endorse it as a useful supplement to other imaging for both diagnosis and ongoing monitoring.
Capsule Endoscopy for Hard-to-Reach Areas
When standard colonoscopy and imaging haven’t provided a clear answer, your doctor may recommend capsule endoscopy. You swallow a pill-sized camera that takes thousands of pictures as it travels through your entire digestive tract. It’s particularly good at catching small, shallow erosions and ulcerations in the small bowel that standard imaging or scopes would miss.
There’s one important safety consideration. If there’s any suspicion of a narrowing or stricture in your bowel, capsule endoscopy is not safe because the camera could get stuck. Doctors typically confirm there’s no obstruction before ordering the test, sometimes using a dissolvable “patency capsule” first. You also can’t have an MRI until the capsule has passed through your system.
Antibody Tests to Tell the Two Apart
When colonoscopy and imaging leave the diagnosis uncertain, antibody blood tests can provide an additional layer of evidence. Two markers are used most often. One, called pANCA, is associated with ulcerative colitis. The other, called ASCA, is associated with Crohn’s disease.
Neither test is accurate enough to diagnose IBD on its own. The pANCA test picks up about 65% of ulcerative colitis cases, and ASCA catches about 61% of Crohn’s cases. But when used in combination, the results become much more telling. A positive ASCA paired with a negative pANCA has a 97% specificity and 96% positive predictive value for Crohn’s disease. The reverse pattern, positive pANCA with negative ASCA, carries 97% specificity and 92% positive predictive value for ulcerative colitis. In practical terms, when both tests point in the same direction, you can be quite confident in the distinction. The limitation is sensitivity: this combination misses roughly half of all cases, so a negative result doesn’t rule anything out.
Why Diagnosis Often Takes So Long
The symptoms of IBD, including diarrhea, abdominal pain, fatigue, and weight loss, overlap with many other conditions. Irritable bowel syndrome, infections, and celiac disease can all look similar in the early stages. Many patients are initially told their symptoms are stress-related or dietary.
Crohn’s disease tends to take longer to diagnose than ulcerative colitis. In patient surveys, 52% of people with Crohn’s reported waiting more than two years for a diagnosis, compared to 37% of those with ulcerative colitis. Part of the reason is that Crohn’s can affect the small bowel, which is harder to examine, and its symptoms can be more variable and intermittent. Ulcerative colitis more often presents with visible rectal bleeding, which tends to prompt earlier investigation.
If your symptoms are persistent and fecal calprotectin comes back elevated, pushing for a colonoscopy referral is reasonable. The combination of a thorough scope exam, biopsies, and appropriate imaging gives doctors the clearest path to separating Crohn’s from ulcerative colitis and starting you on the right treatment.